- Home
- CBIO vs DPG Comparison
CBIO vs DPG Comparison
Compare CBIO & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CBIO | DPG |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.7M | 464.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CBIO | DPG |
|---|---|---|
| Price | $10.83 | $13.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $27.17 | N/A |
| AVG Volume (30 Days) | 142.5K | ★ 150.1K |
| Earning Date | 02-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $7.90 |
| 52 Week High | $21.40 | $13.58 |
Technical Indicators
Market Signals| Indicator | CBIO | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 71.60 |
| Support Level | $10.56 | $12.92 |
| Resistance Level | $14.71 | $13.19 |
| Average True Range (ATR) | 1.01 | 0.15 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 6.14 | 88.34 |
Price Performance
Historical ComparisonAbout CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.